Prognosis of advanced bronchopulmonary cancer
Versandkostenfrei!
Versandfertig in 6-10 Tagen
40,99 €
inkl. MwSt.
PAYBACK Punkte
20 °P sammeln!
Introduction: Primary bronchopulmonary cancer represents the leading cause of cancer mortality in men worldwide. Objective: To evaluate the prognosis of patients with locally advanced and metastatic non-small cell lung carcinoma (NSCLC) and to determine prognostic factors at these stages. Methods: Retrospective study including 140 cases of locally advanced and metastatic NSCLC diagnosed in our department between 2003 and 2013. Results: The mean age was 61±10 years with a clear male predominance. The cancer was stage IIIA in 14%, IIIB in 27% and IV in 59%. Survival at 6 months and 1 year was 5...
Introduction: Primary bronchopulmonary cancer represents the leading cause of cancer mortality in men worldwide. Objective: To evaluate the prognosis of patients with locally advanced and metastatic non-small cell lung carcinoma (NSCLC) and to determine prognostic factors at these stages. Methods: Retrospective study including 140 cases of locally advanced and metastatic NSCLC diagnosed in our department between 2003 and 2013. Results: The mean age was 61±10 years with a clear male predominance. The cancer was stage IIIA in 14%, IIIB in 27% and IV in 59%. Survival at 6 months and 1 year was 50-74% and 9-25%, respectively. Survival was significantly longer in patients with stage III cancer, a performance status (PS) of 0 to 1, comorbidities, prolonged time to positive diagnosis, short treatment time, and who received specific antitumor therapy. Conclusion: Prognostic factors for advanced NSCLC are PS, stage, comorbidities, time to management, and specific antitumor therapy.
Andere Kunden interessierten sich für
